These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9237205)

  • 21. Functionality of intrinsic disorder in tumor necrosis factor-α and its receptors.
    Uversky VN; El-Baky NA; El-Fakharany EM; Sabry A; Mattar EH; Uversky AV; Redwan EM
    FEBS J; 2017 Nov; 284(21):3589-3618. PubMed ID: 28746777
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation.
    Banner DW; D'Arcy A; Janes W; Gentz R; Schoenfeld HJ; Broger C; Loetscher H; Lesslauer W
    Cell; 1993 May; 73(3):431-45. PubMed ID: 8387891
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Characterization of the receptor for tumor necrosis factor (TNF) and lymphotoxin (LT) on human T lymphocytes. TNF and LT differ in their receptor binding properties and the induction of MHC class I proteins on a human CD4+ T cell hybridoma.
    Andrews JS; Berger AE; Ware CF
    J Immunol; 1990 Apr; 144(7):2582-91. PubMed ID: 1969453
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct molecular mechanism for initiating TRAF6 signalling.
    Ye H; Arron JR; Lamothe B; Cirilli M; Kobayashi T; Shevde NK; Segal D; Dzivenu OK; Vologodskaia M; Yim M; Du K; Singh S; Pike JW; Darnay BG; Choi Y; Wu H
    Nature; 2002 Jul; 418(6896):443-7. PubMed ID: 12140561
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Structure-based design and characterization of exocyclic peptidomimetics that inhibit TNF alpha binding to its receptor.
    Takasaki W; Kajino Y; Kajino K; Murali R; Greene MI
    Nat Biotechnol; 1997 Nov; 15(12):1266-70. PubMed ID: 9359109
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tumour necrosis factor and its receptor: a basic structural analysis of two counterparts.
    Wiltgen M; Tilz GP
    Hematology; 2008 Aug; 13(4):224-9. PubMed ID: 18796248
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Sequence and expression analysis of deer mouse interferon-gamma, interleukin-10, tumor necrosis factor, and lymphotoxin-alpha.
    Herbst MM; Prescott J; Palmer AD; Schountz T
    Cytokine; 2002 Feb; 17(4):203-13. PubMed ID: 11991673
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structural and functional domains in human tumour necrosis factors.
    Goh CR; Porter AG
    Protein Eng; 1991 Apr; 4(4):385-9. PubMed ID: 1715560
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mapping the lectin-like activity of tumor necrosis factor.
    Lucas R; Magez S; De Leys R; Fransen L; Scheerlinck JP; Rampelberg M; Sablon E; De Baetselier P
    Science; 1994 Feb; 263(5148):814-7. PubMed ID: 8303299
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Aspartic acid 50 and tyrosine 108 are essential for receptor binding and cytotoxic activity of tumour necrosis factor beta (lymphotoxin).
    Goh CR; Loh CS; Porter AG
    Protein Eng; 1991 Oct; 4(7):785-91. PubMed ID: 1665907
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The structural basis for the recognition of diverse receptor sequences by TRAF2.
    Ye H; Park YC; Kreishman M; Kieff E; Wu H
    Mol Cell; 1999 Sep; 4(3):321-30. PubMed ID: 10518213
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Epitope mapping and functional analysis of three murine IgG1 monoclonal antibodies to human tumor necrosis factor-alpha.
    Bloom JW; Bettencourt JD; Mitra G
    J Immunol; 1993 Sep; 151(5):2707-16. PubMed ID: 7689613
    [TBL] [Abstract][Full Text] [Related]  

  • 33. TNF-Selectokine: a novel prodrug generated for tumor targeting and site-specific activation of tumor necrosis factor.
    Wüest T; Gerlach E; Banerjee D; Gerspach J; Moosmayer D; Pfizenmaier K
    Oncogene; 2002 Jun; 21(27):4257-65. PubMed ID: 12082613
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triggering cell death: the crystal structure of Apo2L/TRAIL in a complex with death receptor 5.
    Hymowitz SG; Christinger HW; Fuh G; Ultsch M; O'Connell M; Kelley RF; Ashkenazi A; de Vos AM
    Mol Cell; 1999 Oct; 4(4):563-71. PubMed ID: 10549288
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of gp39/CD40 interactions using molecular models and site-directed mutagenesis.
    Bajorath J; Marken JS; Chalupny NJ; Spoon TL; Siadak AW; Gordon M; Noelle RJ; Hollenbaugh D; Aruffo A
    Biochemistry; 1995 Aug; 34(31):9884-92. PubMed ID: 7543281
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Seeing double: crystal structures of the type I TNF receptor.
    Naismith JH; Brandhuber BJ; Devine TQ; Sprang SR
    J Mol Recognit; 1996; 9(2):113-7. PubMed ID: 8877801
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A novel domain antibody rationally designed against TNF-alpha using variable region of human heavy chain antibody as scaffolds to display antagonistic peptides.
    Qin W; Feng J; Li Y; Lin Z; Shen B
    Mol Immunol; 2007 Mar; 44(9):2355-61. PubMed ID: 17125837
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Porcine TNF: a review.
    Pauli U
    Vet Immunol Immunopathol; 1995 Aug; 47(3-4):187-201. PubMed ID: 8571540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Human tumor necrosis factor alpha (TNF alpha) mutants with exclusive specificity for the 55-kDa or 75-kDa TNF receptors.
    Loetscher H; Stueber D; Banner D; Mackay F; Lesslauer W
    J Biol Chem; 1993 Dec; 268(35):26350-7. PubMed ID: 8253759
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Release of soluble TNF/LT receptors from a human ovarian tumor cell line (PA-1) by stimulation with cytokines in vitro.
    Gatanaga M; Grosen EA; Burger RA; Granger GA; Gatanaga T
    Lymphokine Cytokine Res; 1993 Aug; 12(4):249-53. PubMed ID: 8218597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.